1
|
Gharraee B, Shabani A, Masoumian S, Zamirinejad S, Yaghmaeezadeh H, Khanjani S, Ghahremani S. Psychometric Properties of Persian Version of Structured Clinical Interview for DSM-5 for Personality Disorders. East Asian Arch Psychiatry 2022; 32:95-99. [PMID: 36578184 DOI: 10.12809/eaap2208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
OBJECTIVES This study aims to examine the psychometric properties of the Persian version of the Structured Clinical Interview for DSM-5 for personality disorders (SCID-5-PD) among patients referred to psychiatric centres in Iran. METHODS Between March 2017 and June 2019, 287 outpatients and inpatients aged 16 to 75 years who were referred to three psychiatric centres in Tehran, Iran were invited to participate. Patients were interviewed using the Persian version of the SCID-5-PD by two PhD students in clinical psychology who were blinded to patient records. Face validity and content validity of the Persian version of the SCID-5-PD were assessed by five specialists with ≥2 years of clinical experience. The agreement between the diagnoses made with the Persian version of the SCID-5-PD by the two PhD students in clinical psychology and the gold standard diagnoses made with DSM-5 by psychiatrists was determined, as were sensitivity, specificity, and positive and negative likelihood ratios. 109 (43.6%) patients were interviewed again after an interval of 7 to 10 days for inter-rater reliability and test-retest reliability. RESULTS A total of 250 patients aged 17 to 74 (mean, 32.56) years were included. Face validity and content validity of the Persian version of SCID-5-PD were acceptable. The agreement between the Persian version of SCID-5-PD and DSM-5 (gold standard) was acceptable (kappa >0.4) for the diagnoses of obsessive-compulsive, paranoid, schizotypal, schizoid, histrionic, narcissistic, borderline, and antisocial personality disorders, whereas the agreement was unacceptable (kappa <0.4) for the diagnoses of avoidant and dependent personality disorders. Sensitivity for all diagnoses was high, except for avoidant (0.66) and dependent (0.66) personality disorders. Specificity for all diagnoses was high, except for avoidant personality disorder (0.66). The positive and negative likelihood ratios showed that the SCID-5-PD was accurate for diagnosing all personality disorders, except for schizoid personality disorder. Inter-rater reliability was good for all personality disorders, except for schizotypal personality disorder (0.531). Test-retest reliability was good for all personality disorders. CONCLUSION The Persian version of the SCID-5-PD can be used to evaluate those who seek psychotherapy for all personality disorders, except for avoidant, dependent, schizoid, and schizotypal personality disorders.
Collapse
Affiliation(s)
- B Gharraee
- Clinical Psychology Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran
| | - A Shabani
- Mental Health Research Center, Mood Disorders Research Group, Iran University of Medical Sciences, Tehran, Iran
| | - S Masoumian
- Clinical Psychology Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran
| | - S Zamirinejad
- Clinical Psychology Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran
| | - H Yaghmaeezadeh
- Clinical Psychology Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran
| | - S Khanjani
- Clinical Psychology Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran
| | - S Ghahremani
- Clinical Psychology Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Farahani L, Mowla S, Tharakan T, Lee Y, Kundu S, Khanjani S, Sindi E, Rai R, Regan L, Ramsay J, Bennett P, Dhillo W, Minhas S, Jayasena C, MacIntyre D. O-252 Next generation sequencing analysis of the seminal microbiome in male partners of women with idiopathic recurrent pregnancy loss: results of a prospective cohort study. Hum Reprod 2022. [DOI: 10.1093/humrep/deac106.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Is there an association between the semen microbiome, seminal reactive oxygen species (ROS) and DNA fragmentation in men with recurrent pregnancy loss (RPL)?
Summary answer
This pilot study outlines the subtle role that microbiota play in influencing ROS and sperm DNA damage for male partners of women with RPL
What is known already
RPL is defined as the loss of two or more consecutive pregnancies. This devastating condition impacts approximately 1% of couples. Paternal causes are not routinely screened for and an underlying cause is not found in up to 50% of cases. Recent studies have reported an association between elevated seminal ROS and sperm DNA fragmentation in the male partner, and RPL. We hypothesised that seminal microbiota contribute to increased ROS and sperm DNA damage. To test this, we investigated the relationship between seminal bacterial composition and ROS levels in men with proven fertility versus men with a history of RPL.
Study design, size, duration
We conducted a prospective, case-control study and recruited participants between November 2018 and March 2020 at Imperial College Healthcare NHS Trust. A total of 109 men participated in the study; 46 men with RPL and 63 men with proven fertility and no history of RPL. Each participant attended for a single study visit which consisted of a full medical history, assessment of testicular volume, height, weight, blood samples and production of a semen sample.
Participants/materials, setting, methods
Routine semen analysis (WHO) and endocrine and lipid profiles were performed for all patients. Semen ROS and DNA fragmentation were performed (luminol and TUNEL methodologies, respectively). ROS were classified as high (>3.77 RLU/s) or low (<3.77 RLU/s). Metataxonomic profiling of samples was performed using Illumina Miseq-based sequencing of the V1-V2 hypervariable regions of bacterial 16S rRNA gene amplicons. Multivariate and univariate modelling was performed to explore associations between metataxonomic profiles, ROS levels and clinical metadata.
Main results and the role of chance
Men with RPL had higher mean semen volume (p = 0.02) and increased prevalence of high ROS (p = 0.02, Fisher's exact) compared with controls; but other clinical characteristics were similar between groups. A total of 3,700,136 high quality sequence reads were generated for the dataset with an average of 33,946 reads/sample. Hierarchical clustering of bacterial genera relative abundances identified 4 distinct microbial signatures characterised by high relative abundance of 1. Streptococcus, 2. Lactobacillus and Gardnerella, 3. polymicrobial (including Prevotella), and 4. Corynebacterium and Finegoldia. Prevalences of these groups were similar in control and RPL groups (p = 0.11). Additionally, no association between the bacterial genera groups and elevated ROS, DNA fragmentation, or clinical factors such as age, ethnicity, or semen volume were observed (chi-square tests). At species taxonomy level relative abundance of L. crispatus was higher in controls compared to RPL, but did not withstand false discovery rate correction for multiple testing (p = 0.006, q = 0.67). Higher relative abundance of Microbacterium was detected in semen samples with high DNA fragmentation (p = 8.7E-4, q = 0.08). This relationship was even stronger within the RPL cohort (p = 2.8E-5, q = 0.002). No significant enrichment of specific taxa was observed between high or low ROS samples however, low ROS was associated with Corynebacterium relative abundance >20%.
Limitations, reasons for caution
More patients are required to enhance statistical power. Duplicate sample collection may establish the robustness of seminal compositions observed. Time since last sexual intercourse samples may affect the analysis. Concomitant analysis of the vaginal microbiome of female partners may improve our understanding of how partners may affect each other’s fertility.
Wider implications of the findings
Our data suggests interactions between microbiota composition, ROS and sperm DNA damage which may be implicated in the pathogenesis of recurrent miscarriage. Further studies are needed to determine if seminal microbiota play causal roles in RPL, and whether interventions modifying the seminal microbiome may modify pregnancy outcomes in affected couples
Trial registration number
not applicable
Collapse
Affiliation(s)
- L Farahani
- Imperial College Healthcare NHS Trust, Obstetrics & Gynaecology , London, United Kingdom
| | - S Mowla
- Imperial College, Institute of Reproductive Developmental Biology , London, United Kingdom
| | - T Tharakan
- Charing Cross Hospital , Urology, London, United Kingdom
| | - Y Lee
- Imperial College, Institute of Reproductive Developmental Biology , London, United Kingdom
| | - S Kundu
- Imperial College, Institute of Reproductive Developmental Biology , London, United Kingdom
| | - S Khanjani
- University College London Hospital , Gynaecology, London, United Kingdom
| | - E Sindi
- Imperial College, Section of Investigative Medicine , London, United Kingdom
| | - R Rai
- Imperial College Healthcare NHS Trust, Obstetrics & Gynaecology , London, United Kingdom
| | - L Regan
- Imperial College Healthcare NHS Trust, Obstetrics & Gynaecology , London, United Kingdom
| | - J Ramsay
- Hammersmith Hospital , Andrology, London, United Kingdom
| | - P Bennett
- Imperial College, Institute of Reproductive Developmental Biology , London, United Kingdom
| | - W Dhillo
- Imperial College, Section of Investigative Medicine , London, United Kingdom
| | - S Minhas
- Charing Cross Hospital , Urology, London, United Kingdom
| | - C Jayasena
- Imperial College, Section of Investigative Medicine , London, United Kingdom
| | - D MacIntyre
- Imperial College, Institute of Reproductive Developmental Biology , London, United Kingdom
| |
Collapse
|
4
|
Di Lorenzo A, Sobolev AP, Nabavi SF, Sureda A, Moghaddam AH, Khanjani S, Di Giovanni C, Xiao J, Shirooie S, Tsetegho Sokeng AJ, Baldi A, Mannina L, Nabavi SM, Daglia M. Corrigendum to "Antidepressive effects of a chemically characterized maqui berry extract (Aristotelia chilensis (molina) stuntz) in a mouse model of Post-stroke depression" [Food Chem. Toxicol. 129 (2019) 434-443]. Food Chem Toxicol 2019; 131:110641. [PMID: 31307821 DOI: 10.1016/j.fct.2019.110641] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- A Di Lorenzo
- Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Viale Taramelli 12, Pavia, 27100, Italy.
| | - A P Sobolev
- Istituto di Metodologie Chimiche, Laboratorio di Risonanza Magnetica "Annalaura Segre", CNR, 00015, Monterotondo, Rome, Italy.
| | - S F Nabavi
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box, 19395-5487, Tehran, 19395-5487, Iran.
| | - A Sureda
- Grup de Nutrició Comunitària I Estrès Oxidatiu and CIBEROBN (Physiopathology of Obesity and Nutrition), Universitat de les Illes Balears, Palma de Mallorca, E-07122, Spain.
| | - A H Moghaddam
- Department of Biology, Faculty of Sciences, University of Mazandaran, Babolsar, Iran.
| | - S Khanjani
- Department of Physiology, Faculty of Biological Sciences, Shahid Behshti University, P.O. Box, 19615-1178, Tehran, 19615-1178, Iran.
| | - C Di Giovanni
- Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 49, 80131, Naples, Italy.
| | - J Xiao
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Control in Chinese Medicine, University of Macau, Macau SAR, China.
| | - S Shirooie
- School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, 6734667149, Iran.
| | - A J Tsetegho Sokeng
- Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Viale Taramelli 12, Pavia, 27100, Italy.
| | - A Baldi
- Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia University, Viale Taramelli 12, Pavia, 27100, Italy.
| | - L Mannina
- Istituto di Metodologie Chimiche, Laboratorio di Risonanza Magnetica "Annalaura Segre", CNR, 00015, Monterotondo, Rome, Italy; Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le Aldo Moro 5, 00185, Rome, Italy.
| | - S M Nabavi
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box, 19395-5487, Tehran, 19395-5487, Iran.
| | - M Daglia
- Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 49, 80131, Naples, Italy.
| |
Collapse
|
5
|
Owens LA, Abbara A, Lerner A, O'floinn S, Christopoulos G, Khanjani S, Islam R, Hardy K, Hanyaloglu AC, Lavery SA, Dhillo WS, Franks S. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. Hum Reprod 2019; 33:292-302. [PMID: 29206944 DOI: 10.1093/humrep/dex357] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 11/13/2017] [Indexed: 11/12/2022] Open
Abstract
STUDY QUESTION What are the in vivo and in vitro actions of kisspeptin-54 on the expression of genes involved in ovarian reproductive function, steroidogenesis and ovarian hyperstimulation syndrome (OHSS) in granulosa lutein (GL) cells when compared with traditional triggers of oocyte maturation? SUMMARY ANSWER The use of kisspeptin-54 as an oocyte maturation trigger augmented expression of genes involved in ovarian steroidogenesis in human GL cells including, FSH receptor (FSHR), LH/hCG receptor (LHCGR), steroid acute regulatory protein (STAR), aromatase, estrogen receptors alpha and beta (ESR1, ESR2), 3-beta-hydroxysteroid dehydrogenase type 2 (3BHSD2) and inhibin A (INHBA), when compared to traditional maturation triggers, but did not alter markers of OHSS. WHAT IS KNOWN ALREADY hCG is the most widely used trigger of oocyte maturation, but is associated with an increased risk of OHSS. The use of GnRH agonists to trigger oocyte maturation is a safer alternative to hCG. More recently, kisspeptin-54 has emerged as a novel therapeutic option that safely triggers oocyte maturation even in women at high risk of OHSS. Kisspeptin indirectly stimulates gonadotropin secretion by acting on hypothalamic GnRH neurons. Kisspeptin and its receptor are also expressed in the human ovary, but there is limited data on the direct action of kisspeptin on the ovary. STUDY DESIGN SIZE, DURATION Forty-eight women undergoing IVF treatment for infertility consented to kisspeptin-54 triggering and/or granulosa cell collection and were included in the study. Twelve women received hCG, 12 received GnRH agonist and 24 received kisspeptin-54 to trigger oocyte maturation. In the kisspeptin-54 group, 12 received one injection of kisseptin-54 (9.6 nmol/kg) and 12 received two injections of kisspeptin-54 at a 10 h interval (9.6 nmol/kg × 2). PARTICIPANTS/MATERIALS, SETTING, METHODS Follicular fluid was aspirated and pooled from follicles during the retrieval of oocytes for IVF/ICSI. GL cells were isolated and either RNA extracted immediately or cultured in vitro ± kisspeptin or hCG. MAIN RESULTS AND THE ROLE OF CHANCE GL cells from women who had received kisspeptin-54 had a 14-fold and 8-fold higher gene expression of FSHR and a 2-fold (ns) and 2.5-fold (P < 0.05) higher expression of LHCGR than GL cells from women who had received hCG or GnRH agonist, respectively. CYP19A1 expression was 3.6-fold (P < 0.05) and 4.5-fold (P < 0.05) higher, STAR expression was 3.4-fold (P < 0.01) and 1.8-fold (P < 0.05) higher, HSD3B2 expression was 7.5- (P < 0.01) and 2.5-fold higher (P < 0.05), INHBA was 2.5-fold (P < 0.01) and 2.5-fold (P < 0.01) higher in GL cells from women who had received kisspeptin-54 than hCG or GnRHa, respectively. ESR1 (P < 0.05) and ESR2 (P < 0.05) both showed 3-fold higher expression in cells from kisspeptin treated than GnRHa treated women. Markers of vascular permeability and oocyte growth factors were unchanged (VEGFA, SERPINF1, CDH5, amphiregulin, epiregulin). Gene expression of kisspeptin receptor was unchanged. Whereas treating GL cells in vitro with hCG induced steroidogenic gene expression, kisspeptin-54 had no significant direct effects on either OHSS genes or steroidogenic genes. LIMITATIONS REASONS FOR CAUTION Most women in the study had PCOS, which may limit applicability to other patient groups. For the analysis of the in vitro effects of kisspeptin-54, it is important to note that GL cells had already been exposed in vivo to an alternate maturation trigger. WIDER IMPLICATIONS OF THE FINDINGS The profile of serum gonadotropins seen with kisspeptin administration compared to other triggers more closely resemble that of the natural cycle as compared with hCG. Thus, kisspeptin could potentially permit an ovarian environment augmented for steroidogenesis, in particular progesterone synthesis, which is required for embryo implantation. STUDY FUNDING/COMPETING INTEREST(S) Dr Owens is supported by an Imperial College London PhD Scholarship. Dr Abbara is supported by an National Institute of Health Research Academic Clinical Lectureship. The authors do not have any conflict of interest to declare. TRIAL REGISTRATION NUMBER ClinicalTrials.gov NCT01667406.
Collapse
Affiliation(s)
- L A Owens
- Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, UK
| | - A Abbara
- Department of Investigative Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - A Lerner
- Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, UK
| | - S O'floinn
- Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, UK
| | - G Christopoulos
- Department of Reproductive Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0NN, UK
| | - S Khanjani
- Department of Reproductive Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0NN, UK
| | - R Islam
- Department of Reproductive Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0NN, UK
| | - K Hardy
- Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, UK
| | - A C Hanyaloglu
- Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, UK
| | - S A Lavery
- Department of Reproductive Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0NN, UK
| | - W S Dhillo
- Department of Investigative Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
| | - S Franks
- Institute of Reproductive and Developmental Biology, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 0NN, UK
| |
Collapse
|
7
|
Palial KK, Drury J, Heathcote L, Valentijin A, Farquharson RG, Gazvani R, Rudland PS, Hapangama DK, Celik N, Celik O, Aktan E, Ozerol E, Celik E, Bozkurt K, Paran H, Hascalik S, Ozerol I, Arase T, Maruyama T, Uchida H, Miyazaki K, Oda H, Uchida-Nishikawa S, Kagami M, Yamazaki A, Tamaki K, Yoshimura Y, De Vos M, Ortega C, Smitz J, Van Vaerenbergh I, Bourgain C, Devroey P, Luciano D, Exacoustos C, Zupi E, Luciano AA, Arduini D, Palomino WA, Argandona F, Kohen P, Azua R, Scarella A, Devoto L, McKinnon B, Bersinger NA, Mueller MD, Bonavita M, Mattila M, Ferreira FP, Maia-Filho V, Rocha AM, Serafini P, Motta ELA, Kim H, Kim CH, You RM, Nah HY, Lee JW, Kang HJ, Kang BM, Letur - Koenirsch H, Haouzi D, Olivennes F, Rouleau C, Cohen-Bacri P, Dechaud H, Hamamah S, D'Hooghe T, Hummelshoj L, Dunselman GAJ, Dirksen CD, EndoCost Consortium WERF, Simoens S, Novembri R, Luisi S, Carrarelli P, Rocha ALL, Toti P, Reis FM, Florio P, Petraglia F, Bruce KD, Sadek KH, Macklon N, Cagampang FR, Cheong Y, Goudakou M, Kalogeraki A, Matalliotakis I, Papatheodorou A, Pasadaki T, Karkanaki A, Prapas I, Prapas I, Kalogeraki A, Matalliotakis I, Panagiotidis I, Kasapi E, Karkanaki A, Goudakou M, Barlow D, Oliver J, Loumaye E, Khanmohammadi M, kazemnejad S, darzi S, Khanjani S, Zarnani A, Akhondi M, Tan CW, Ng CP, Loh SF, Tan HH, Choolani M, Griffith L, Chan J, Andersson KL, Sundqvist J, Scarselli G, Gemzell-Danielsson K, Lalitkumar PG, Jana S, Chattopadhyay R, Datta Ray C, Chaudhury K, Chakravarty BN, Hannan N, Evans J, Hincks C, Rombauts LJF, Salamonsen LA, Choi D, Lee J, Park J, Chang H, Kim M, Hwang K, Takeuchi K, Kurematsu T, Fukumoto Y, Yuki Y, Kuroki Y, Homan Y, Sata Y, Takeuchi M, Munoz Munoz E, Ortiz Olivera G, Fernandez Lopez I, Martinez Martinez B, Aguilar Prieto J, Portela Perez S, Pellicer Martinez A, Keltz M, Sauerbrun M, Breborowicz A, Gonzales E, Vicente-Munoz S, Puchades-Carrasco L, Morcillo I, Hidalgo JJ, Gilabert-Estelles J, Novella-Maestre E, Pellicer A, Pineda-Lucena A, Yavorovskaya KA, Okhtyrskaya TA, Demura TA, Faizulina NM, Ezhova LS, Kogan EA, Bilibio JP, Souza CAB, Rodini GP, Genro V, Andreoli CG, de Conto E, Cunha-Filho JSL, Saare M, Soritsa D, Jarva L, Vaidla K, Palta P, Laan M, Karro H, Soritsa A, Salumets A, Peters M, Miskova A, Pilmane M, Rezeberga D, Haouzi D, Dechaud H, Assou S, Letur H, Olivennes F, Hamamah S, Piomboni P, Stendardi A, Gambera L, De Leo V, Petraglia F, Focarelli R, Tamm K, Simm J, Salumets A, Metsis M, Vodolazkaia A, Fassbender A, Kyama CM, Bokor A, Schols D, Huskens D, Meuleman C, Peeraer K, Tomassetti C, D'Hooghe TM, Machens K, Afhuppe W, Schulz A, Diefenbach K, Schutt B, Faustmann T, Reischl J, Peters M, Altmae S, Reimand J, Laisk T, Saare M, Hovatta O, Kolde R, Vilo J, Stavreus-Evers A, Salumets A, Lee JH, Kim SG, Kim YY, Park IH, Sun HG, Lee KH, Ezoe K, Kawano H, Yabuuchi A, Ochiai K, Nagashima H, Osada H, Kagawa N, Kato O, Tamura I, Asada H, Taketani T, Tamura H, Sugino N, Garcia Velasco J, Prieto L, Quesada JF, Cambero O, Toribio M, Pellicer A, Hur CY, Lim KS, Lee WD, Lim JH, Germeyer A, Nelson L, Graham A, Jauckus J, Strowitzki T, Lessey B, Gyulmamedova I, Illina O, Illin I, Mogilevkina I, Chaika A, Nosenko O, Boykova I, Gulmamedova E, Isik H, Moraloglu O, Seven ALI, Kilic S, Erkayiran U, Caydere M, Batioglu S, Alhalabi M, Samawi S, Taha A, Kafri N, Modi S, Khatib A, Sharif J, Othman A, Lancuba S, Branzini C, Lopez M, Baricalla A, Cristina C, Chen J, Jiang Y, Zhen X, Hu Y, Yan G, Sun H, Mizumoto J, Ueno J, Carvalho FM, Casals G, Ordi J, Guimera M, Creus M, Fabregues F, Casamitjana R, Carmona F, Balasch J, Choi YS, Kim KC, Lee WD, Kim KH, Lee BS, Kim SH, Fassbender A, Overbergh L, Verdrengh E, Kyama C, Vodolazkaia A, Bokor A, Meuleman C, Peeraer K, Tomassetti C, Waelkens E, Mathieu C, D'Hooghe T, Iwasa T, Hatano K, Hasegawa E, Ito H, Isaka K, L. Rocha AL, Luisi S, Carrarelli P, Novembri R, Florio P, Reis F, Petraglia F, Lee KS, Joo JK, Son JB, Choi JR, Vidali A, Barad DH, Gleicher N, Jiang Y, Chen J, Zhen X, Hu Y, Sun H, Yan G, Sayyah-Melli M, Kazemi-Shishvan M. POSTER VIEWING SESSION - ENDOMETRIOSIS, ENDOMETRIUM, IMPLANTATION AND FALLOPIAN TUBE. Hum Reprod 2011. [DOI: 10.1093/humrep/26.s1.80] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|